AI in Medical Imaging Market to Reach $8.56 Billion by 2030 at 30% CAGR | GE Healthcare, Butterfly Network, Enlitic Among Key Players

The global AI in medical imaging market, valued at $1.75 billion in 2024, will reach $8.56 billion by 2030, expanding at a compound annual growth rate (CAGR) of 30% over the forecast period. The scale of that growth reflects a fundamental shift in how diagnostic imaging is processed, interpreted, and acted upon across healthcare systems worldwide.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/deep-learning-market/request-sample.html

Market Overview
Medical imaging generates approximately 90% of all data produced in hospital environments. That volume exceeds what radiologists can process accurately and at pace, and the consequences are measurable: roughly 15% of medical cases in developed countries are misdiagnosed, contributing to an estimated 1.5 million deaths annually from diagnostic error worldwide. AI systems built on deep learning algorithms address this directly, automating the reading of X-rays, CT scans, MRI, and ultrasound data with a precision that supplements, and in many cases outpaces, manual review.

The efficiency case is well-documented. AI-driven interpretation of radiology data can accelerate processing by 20% while cutting false positive rates by approximately 10%. That calculus, combined with a projected shortage of 10,000 to 40,000 physicians in the United States alone by 2030, has drawn sustained interest from venture capital firms, strategic investors, and technology majors. IBM, GE Healthcare, and Google have each entered into alliances with pharmaceutical and healthcare organizations to bring proprietary deep learning imaging solutions to clinical use. More than $2 billion has already been invested by stakeholders developing such tools.

Regulatory momentum is building alongside commercial activity. The FDA has cleared a growing number of AI imaging software applications, and recent approvals are accelerating. In March 2026, Harrison.ai received FDA clearance for its acute infarct triage software on non-contrast CT brain scans. That same month, Radiology Partners secured FDA Breakthrough Device designation for its Cognita Chest X-ray solution, which uses a generative vision-language model to draft radiology reports for physician review. Also in March 2026, RadNet announced the acquisition of Gleamer for up to EUR 230 million, signaling an aggressive push to broaden AI clinical offerings and extend European reach.

Key Growth Drivers
Physician shortfall and imaging volume pressure. The gap between radiologist capacity and diagnostic demand continues to widen in both mature and emerging healthcare markets. Deep learning systems are filling that gap in high-volume environments, particularly in settings where physician-to-patient ratios are structurally low. This operational necessity is the single largest demand driver for AI in medical imaging.

Adoption of precision and personalized medicine. Healthcare systems are moving toward treatment protocols built on individual patient data rather than population averages. AI imaging tools that can detect sub-clinical patterns, including spatial and temporal changes not visible to the human eye, directly enable this shift, making them integral to oncology, neurology, and cardiovascular care pathways.

FDA clearances and regulatory maturation. Each regulatory approval expands the addressable market for AI imaging vendors. The pace of FDA clearances has increased materially, and developers are actively pursuing Breakthrough Device designation to shorten time-to-market. This regulatory tailwind is converting clinical-stage solutions into commercial products at a faster rate than in prior years.

Strategic partnerships deepening market penetration. Deal activity across the sector is intensifying. In December 2023, Enlitic integrated its ENDEX data standardization solution with INFINITT PACS. In October 2023, Aidoc expanded its partnership with GLEAMER to deploy ChestView AI across CT and X-ray systems. In June 2023, EchoNous and UltraSight combined real-time AI guidance with handheld ultrasound hardware for cardiac imaging. These agreements are extending AI capabilities into existing hospital infrastructure without requiring full system replacements.

Cost savings at the system level. Beyond clinical accuracy, AI imaging tools generate measurable economic value for hospital networks and payers. Early and accurate diagnosis reduces downstream treatment costs, redundant imaging, and prolonged hospital stays. Cost-saving analyses conducted across approximately 30 countries confirm that AI adoption in radiology produces material savings at scale.

Market Segmentation
The AI in medical imaging market segments by application area, type of image processed, and geography. By application, brain abnormalities and neurological disorders hold the largest share of both current and forecast revenue, driven by the high diagnostic complexity of neuroimaging and the clinical consequences of missed diagnoses in stroke and traumatic brain injury. Lung cancer and respiratory disorders represent the second major application cluster, given the global burden of pulmonary disease and the high volume of chest imaging performed annually.

By image type, CT processing accounts for 42% of current solutions on the market, followed by MRI at 24%, X-ray at 21%, and ultrasound at 16%. X-ray, however, is the fastest-growing sub-segment in terms of new solution launches, with close to 30% of market players offering dedicated X-ray tools, reflecting both the accessibility of X-ray infrastructure in lower-resource settings and the generative AI advances now being applied to chest X-ray interpretation.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/deep-learning-market/request-quote.html

Regional Insights
North America dominates the AI in medical imaging market, accounting for close to 70% of the global opportunity. The region's leadership reflects its concentration of AI imaging companies, the maturity of its regulatory framework, and the depth of venture and strategic investment flowing into the sector. The United States, in particular, is the primary hub for both product development and early commercial adoption, supported by FDA's increasingly active stance on AI software approvals.

Europe is the second-largest regional market and is gaining ground through consolidation. The RadNet acquisition of Gleamer, completed in early 2026, illustrates how North American players are moving into European infrastructure to capture share. Asia Pacific represents the fastest-growing regional segment, where rising healthcare expenditure, expanding hospital networks, and government digitization initiatives are accelerating uptake of AI diagnostic tools.

Competitive Landscape
Key companies profiled in the Roots Analysis report include Artelus, Arterys, Butterfly Network, ContextVision, Enlitic, EchoNous, GE Healthcare, InferVision, and VUNO. The full report covers more than 495 companies active in the AI in medical imaging space globally.

The market remains well-fragmented, with large technology firms and pure-play AI developers competing alongside early-stage innovators. The primary competitive battleground has shifted from product development to regulatory clearance, clinical validation, and distribution reach. M&A activity is intensifying as established players acquire specialized AI capabilities to fill portfolio gaps, while startups continue to challenge incumbents with single-indication tools built for speed and clinical specificity.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/deep-learning-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.